Litcius/Paper detail

Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L)

Akira Hamada, Junichi Soh, Akito Hata, Kiyoshi Nakamatsu, Mototsugu Shimokawa, Yasushi Yatabe, Hiroyuki Oizumi, Masahiro Tsuboi, Hidehito Horinouchi, Ichiro Yoshino, Masayuki Tanahashi, Shinichi Toyooka, Morihito Okada, Hiroyasu Yokomise, Motohiro Yamashita, Yasumasa Nishimura, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Tetsuya Mitsudomi

2021Clinical Lung Cancer26 citationsDOI

Topics & Concepts

MedicineLung cancerOncologyRadiation therapyNeoadjuvant therapyClinical endpointInternal medicineMediastinal lymph nodeClinical trialDurvalumabLymph nodeCarboplatinSurgeryCancerImmunotherapyChemotherapyBreast cancerCisplatinNivolumabMetastasisLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L) | Litcius